Company / Operating Cash Flow
RAPT Therapeutics, Inc. Operating Cash Flow History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$83.3M
FY2024
5-year range
-$97.0M / -$40.5M
FY2020-FY2024
Trend
+14.2%
vs FY2023
Sector context
#118 of 215
Health Care
What the data says
At -$83M, RAPT Therapeutics, Inc.'s operating cash flow ranks #118 of 215 in the Health Care sector. Operating Cash Flow returned to growth in FY2024 after 5 years of decline, reaching -$83M.
Based on SEC 10-K filings.
-$83M in FY2024.
Declined from -$71M to -$83M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#118 of 215 in Health CareTop 55% of 215This company -$83.3M Sector average $661.2M
▼
-112.6% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow increased 14.2% year-over-year.
- Ranks #118 out of 215 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2018.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$83.3M | +14.2% |
| FY2023 | -$97.0M | -37.1% |
| FY2022 | -$70.8M | -16.0% |
| FY2021 | -$61.0M | -50.7% |
| FY2020 | -$40.5M | -14.1% |
| FY2019 | -$35.5M | -7.7% |
| FY2018 | -$33.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026